ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 46.93M | 66.89M | 130.10M | 122.20M | 43.80M | |||
| Marketable Securities | 205.58M | 176.64M | 47.50M | 72.10M | N/A | |||
| Receivables | N/A | N/A | N/A | 0.00 | 100.00K | |||
| Other Current Assets | 3.32M | 3.09M | 2.70M | 4.40M | 500.00K | |||
| Total Current Assets | 255.83M | 246.62M | 180.30M | 198.70M | 44.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 470.00K | 503.00K | 300.00K | 0.00 | N/A | |||
| Investments And Advances | 44.11M | 62.55M | 15.80M | 31.60M | N/A | |||
| Other Non-Current Assets | 558.00K | 454.00K | 200.00K | 0.00 | 0.00 | |||
| Total Non-Current Assets | 45.14M | 63.51M | 16.30M | 31.60M | 0.00 | |||
| TOTAL ASSETS | 300.97M | 310.13M | 196.60M | 230.30M | 44.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 756.00K | N/A | N/A | N/A | |||
| Accrued Expenses | 4.91M | 10.62M | 6.00M | 3.90M | 300.00K | |||
| Accounts Payable | 3.08M | 1.38M | 1.60M | 1.10M | 500.00K | |||
| Other Current Liabilities | 481.00K | 212.00K | 100.00K | 200.00K | 5.50M | |||
| Total Current Liabilities | 8.47M | 12.97M | 7.80M | 5.10M | 6.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 30.21M | 29.90M | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 252.00K | 284.00K | N/A | 0.00 | N/A | |||
| Total Non-Current Liabilities | 30.46M | 30.18M | 0.00 | 0.00 | 0.00 | |||
| TOTAL LIABILITIES | 38.93M | 43.15M | 7.80M | 5.10M | 6.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -237.67M | -222.80M | -170.40M | -127.60M | -27.00M | |||
| Additional Paid In Capital | 499.84M | 489.45M | 359.90M | 353.00M | 8.40M | |||
| Common Shares | 6.00K | 6.00K | 0.00 | 0.00 | 56.70M | |||
| Other Shareholders' Equity | -144.00K | 312.00K | -800.00K | -200.00K | N/A | |||
| Shares Outstanding | 60.08M | 57.91M | 41.00M | 40.50M | 38.70M | |||
| Tangible Book Value per Share | 4.36 | 4.61 | 4.60 | 5.56 | -0.48 | |||
| Total Shareholders' Equity | 262.03M | 266.97M | 188.80M | 225.20M | 38.10M | |||
| TOTAL LIABILITIES AND EQUITY | 300.97M | 310.13M | 196.60M | 230.30M | 44.40M | |||
| Statistics | ||||||||
| Debt/Equity | 0.12 | 0.11 | N/A | N/A | N/A | |||
| Current Ratio | 30.20 | 19.01 | 23.12 | 38.96 | 6.94 | |||
| Return On Assets (ROA) | -18.59% | -16.89% | -21.80% | -43.69% | -16.51% | |||
| Return On Equity (ROE) | -21.35% | -19.62% | -22.70% | -44.68% | -19.24% | |||
All data in USD